---
document_datetime: 2025-12-02 05:38:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oxbryta.html
document_name: oxbryta.html
version: success
processing_time: 0.1096265
conversion_datetime: 2025-12-28 00:27:54.097919
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oxbryta

[RSS](/en/individual-human-medicine.xml/67525)

##### Suspended

This medicine is currently suspended from use in the European Union

voxelotor Medicine Human Suspended

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Oxbryta](#news-on)
- [More information on Oxbryta](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Oxbryta is a medicine used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease. Oxbryta can be given on its own or together with another medicine for sickle cell disease called hydroxycarbamide.

Sickle cell disease is a genetic disease where individuals produce an abnormal form of haemoglobin (the protein in red blood cells that carries oxygen). The red blood cells become rigid and sticky, and change from being disc-shaped to being crescent-shaped (like a sickle). Sickle cell disease is rare, and Oxbryta was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1769](/en/medicines/human/orphan-designations/eu-3-16-1769) .

Oxbryta contains the active substance voxelotor.

Expand section

Collapse section

## How is Oxbryta used?

Oxbryta can only be obtained with a prescription and treatment should be started by a doctor experienced in the treatment of sickle cell disease.

The medicine is available as tablets to be taken by mouth and the usual recommended dose is 1,500 mg taken once daily.

For more information about using Oxbryta, see the package leaflet or contact your doctor or pharmacist.

## How does Oxbryta work?

In sickle cell disease, sickling of the red blood cells occurs when the abnormal haemoglobin releases its oxygen and then clumps together to form rigid chains that make the cells change shape and cause them to break down more quickly. As well as potentially blocking blood vessels, this leads to lower numbers of red blood cells and less working haemoglobin able to carry oxygen around the body. The active substance in Oxbryta, voxelotor, works by improving the ability of the haemoglobin to hold on to oxygen, and preventing it from forming chains. This helps the red blood cells to maintain normal shape and flexibility, reducing their excess breakdown and improving their lifespan.

## What benefits of Oxbryta have been shown in studies?

Oxbryta has been shown to improve haemolytic anaemia in a main study involving 247 patients aged 12 to 64 years with sickle cell disease. Patients were given Oxbryta or placebo (a dummy treatment) as well as continuing hydroxycarbamide treatment if they were already receiving it. At the start of treatment, the average haemoglobin level was 8.5 g per dL of blood. After treatment for 24 weeks, the haemoglobin level had improved by at least 1 g per dL in around 51% of the group given Oxbryta 1,500 mg daily (46 of 90 patients) versus 6.5% of those taking placebo (6 of 92). Other measures also showed reductions in red blood cell breakdown with Oxbryta.

## What are the risks associated with Oxbryta?

The most common side effects with Oxbryta (which may affect more than 1 in 10 people) are headache, diarrhoea and abdominal (belly) pain. The most serious side effects, affecting around 1 in 100 people, include headache and hypersensitivity (allergic) reactions.

For the full list of side effects and restrictions with Oxbryta, see the package leaflet.

## Why is Oxbryta authorised in the EU?

Current treatments for sickle cell disease already include medicines to prevent the painful crises caused when sickle cells block blood supply to vital organs. However, there is an unmet medical need for treatments to manage the anaemia associated with the condition, which leads to tiredness and chronic pain as well as contributing to other complications. Oxbryta has been shown to improve anaemia by increasing haemoglobin levels and reducing red cell breakdown. It is not yet clear to what extent this will improve clinical symptoms and quality of life in the longer term, since the medicine's action may also reduce the ability of haemoglobin to release oxygen to the body's tissues. Nonetheless, since the side effects seem to be limited and manageable, the European Medicines Agency decided that Oxbryta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oxbryta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxbryta have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Oxbryta are continuously monitored. Suspected side effects reported with Oxbryta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Oxbryta

Oxbryta received a marketing authorisation valid throughout the EU on 14 February 2022.

Oxbryta : EPAR - Medicine Overview

Reference Number: EMA/131392/2022

English (EN) (119.37 KB - PDF)

**First published:** 17/03/2022

[View](/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-572)

български (BG) (142.48 KB - PDF)

**First published:**

17/03/2022

[View](/bg/documents/overview/oxbryta-epar-medicine-overview_bg.pdf)

español (ES) (118.74 KB - PDF)

**First published:**

17/03/2022

[View](/es/documents/overview/oxbryta-epar-medicine-overview_es.pdf)

čeština (CS) (141.29 KB - PDF)

**First published:**

17/03/2022

[View](/cs/documents/overview/oxbryta-epar-medicine-overview_cs.pdf)

dansk (DA) (116.58 KB - PDF)

**First published:**

17/03/2022

[View](/da/documents/overview/oxbryta-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.91 KB - PDF)

**First published:**

17/03/2022

[View](/de/documents/overview/oxbryta-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.85 KB - PDF)

**First published:**

17/03/2022

[View](/et/documents/overview/oxbryta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.39 KB - PDF)

**First published:**

17/03/2022

[View](/el/documents/overview/oxbryta-epar-medicine-overview_el.pdf)

français (FR) (119.56 KB - PDF)

**First published:**

17/03/2022

[View](/fr/documents/overview/oxbryta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.4 KB - PDF)

**First published:**

17/03/2022

[View](/hr/documents/overview/oxbryta-epar-medicine-overview_hr.pdf)

italiano (IT) (117.37 KB - PDF)

**First published:**

17/03/2022

[View](/it/documents/overview/oxbryta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (137.8 KB - PDF)

**First published:**

17/03/2022

[View](/lv/documents/overview/oxbryta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (141.74 KB - PDF)

**First published:**

17/03/2022

[View](/lt/documents/overview/oxbryta-epar-medicine-overview_lt.pdf)

magyar (HU) (139.99 KB - PDF)

**First published:**

17/03/2022

[View](/hu/documents/overview/oxbryta-epar-medicine-overview_hu.pdf)

Malti (MT) (144.96 KB - PDF)

**First published:**

17/03/2022

[View](/mt/documents/overview/oxbryta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118 KB - PDF)

**First published:**

17/03/2022

[View](/nl/documents/overview/oxbryta-epar-medicine-overview_nl.pdf)

polski (PL) (144.55 KB - PDF)

**First published:**

17/03/2022

[View](/pl/documents/overview/oxbryta-epar-medicine-overview_pl.pdf)

português (PT) (119.41 KB - PDF)

**First published:**

17/03/2022

[View](/pt/documents/overview/oxbryta-epar-medicine-overview_pt.pdf)

română (RO) (139.77 KB - PDF)

**First published:**

17/03/2022

[View](/ro/documents/overview/oxbryta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.29 KB - PDF)

**First published:**

17/03/2022

[View](/sk/documents/overview/oxbryta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.74 KB - PDF)

**First published:**

17/03/2022

[View](/sl/documents/overview/oxbryta-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.98 KB - PDF)

**First published:**

17/03/2022

[View](/fi/documents/overview/oxbryta-epar-medicine-overview_fi.pdf)

svenska (SV) (117.01 KB - PDF)

**First published:**

17/03/2022

[View](/sv/documents/overview/oxbryta-epar-medicine-overview_sv.pdf)

Oxbryta : EPAR - Risk management plan summary

English (EN) (165.06 KB - PDF)

**First published:** 17/03/2022

[View](/en/documents/rmp-summary/oxbryta-epar-risk-management-plan-summary_en.pdf)

## Product information

Oxbryta : EPAR - Product Information

English (EN) (636.65 KB - PDF)

**First published:** 17/03/2022

**Last updated:** 04/06/2024

[View](/en/documents/product-information/oxbryta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-781)

български (BG) (539.84 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/bg/documents/product-information/oxbryta-epar-product-information_bg.pdf)

español (ES) (330.22 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/es/documents/product-information/oxbryta-epar-product-information_es.pdf)

čeština (CS) (501.83 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/cs/documents/product-information/oxbryta-epar-product-information_cs.pdf)

dansk (DA) (488.71 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/da/documents/product-information/oxbryta-epar-product-information_da.pdf)

Deutsch (DE) (515.88 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/de/documents/product-information/oxbryta-epar-product-information_de.pdf)

eesti keel (ET) (510 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/et/documents/product-information/oxbryta-epar-product-information_et.pdf)

ελληνικά (EL) (529.47 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/el/documents/product-information/oxbryta-epar-product-information_el.pdf)

français (FR) (362.27 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/fr/documents/product-information/oxbryta-epar-product-information_fr.pdf)

hrvatski (HR) (344.3 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/hr/documents/product-information/oxbryta-epar-product-information_hr.pdf)

íslenska (IS) (336.92 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/is/documents/product-information/oxbryta-epar-product-information_is.pdf)

italiano (IT) (331.19 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/it/documents/product-information/oxbryta-epar-product-information_it.pdf)

latviešu valoda (LV) (359.96 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/lv/documents/product-information/oxbryta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (348.28 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/lt/documents/product-information/oxbryta-epar-product-information_lt.pdf)

magyar (HU) (390.12 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/hu/documents/product-information/oxbryta-epar-product-information_hu.pdf)

Malti (MT) (370.96 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/mt/documents/product-information/oxbryta-epar-product-information_mt.pdf)

Nederlands (NL) (513.4 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/nl/documents/product-information/oxbryta-epar-product-information_nl.pdf)

norsk (NO) (333 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/no/documents/product-information/oxbryta-epar-product-information_no.pdf)

polski (PL) (332.58 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/pl/documents/product-information/oxbryta-epar-product-information_pl.pdf)

português (PT) (352.02 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/pt/documents/product-information/oxbryta-epar-product-information_pt.pdf)

română (RO) (349.65 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/ro/documents/product-information/oxbryta-epar-product-information_ro.pdf)

slovenčina (SK) (350.08 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/sk/documents/product-information/oxbryta-epar-product-information_sk.pdf)

slovenščina (SL) (329.05 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/sl/documents/product-information/oxbryta-epar-product-information_sl.pdf)

Suomi (FI) (432.68 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/fi/documents/product-information/oxbryta-epar-product-information_fi.pdf)

svenska (SV) (335.59 KB - PDF)

**First published:**

17/03/2022

**Last updated:**

04/06/2024

[View](/sv/documents/product-information/oxbryta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010983/202308 17/05/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Oxbryta : EPAR - All authorised presentations

English (EN) (45.96 KB - PDF)

**First published:** 17/03/2022

[View](/en/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-418)

български (BG) (62.99 KB - PDF)

**First published:**

17/03/2022

[View](/bg/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.53 KB - PDF)

**First published:**

17/03/2022

[View](/es/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.18 KB - PDF)

**First published:**

17/03/2022

[View](/cs/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.06 KB - PDF)

**First published:**

17/03/2022

[View](/da/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (47.53 KB - PDF)

**First published:**

17/03/2022

[View](/de/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.25 KB - PDF)

**First published:**

17/03/2022

[View](/et/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.9 KB - PDF)

**First published:**

17/03/2022

[View](/el/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_el.pdf)

français (FR) (47.11 KB - PDF)

**First published:**

17/03/2022

[View](/fr/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (113.5 KB - PDF)

**First published:**

17/03/2022

[View](/hr/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.95 KB - PDF)

**First published:**

17/03/2022

[View](/is/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.93 KB - PDF)

**First published:**

17/03/2022

[View](/it/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.47 KB - PDF)

**First published:**

17/03/2022

[View](/lv/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.34 KB - PDF)

**First published:**

17/03/2022

[View](/lt/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.96 KB - PDF)

**First published:**

17/03/2022

[View](/hu/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57.19 KB - PDF)

**First published:**

17/03/2022

[View](/mt/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.62 KB - PDF)

**First published:**

17/03/2022

[View](/nl/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.57 KB - PDF)

**First published:**

17/03/2022

[View](/no/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.65 KB - PDF)

**First published:**

17/03/2022

[View](/pl/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.95 KB - PDF)

**First published:**

17/03/2022

[View](/pt/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.76 KB - PDF)

**First published:**

17/03/2022

[View](/ro/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (84.9 KB - PDF)

**First published:**

17/03/2022

[View](/sk/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (85.55 KB - PDF)

**First published:**

17/03/2022

[View](/sl/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.04 KB - PDF)

**First published:**

17/03/2022

[View](/fi/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (62.67 KB - PDF)

**First published:**

17/03/2022

[View](/sv/documents/all-authorised-presentations/oxbryta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Oxbryta Active substance voxelotor International non-proprietary name (INN) or common name voxelotor Therapeutic area (MeSH)

- Anemia
- Anemia, Hemolytic
- Anemia, Sickle Cell

Anatomical therapeutic chemical (ATC) code B06AX03

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

## Authorisation details

EMA product number EMEA/H/C/004869

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 16/12/2021 Marketing authorisation issued 14/02/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oxbryta Article-20 procedure - Assessment report on temporary measures

Adopted

Reference Number: EMA/460760/2024

English (EN) (1019.1 KB - PDF)

**First published:** 08/10/2024

[View](/en/documents/referral/oxbryta-article-20-procedure-assessment-report-temporary-measures_en.pdf)

Oxbryta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (136.15 KB - PDF)

**First published:** 13/04/2022

**Last updated:** 04/06/2024

[View](/en/documents/procedural-steps-after/oxbryta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Oxbryta-H-C-PSUSA-00010983-202308 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/104734/2024

English (EN) (118.55 KB - PDF)

**First published:** 04/06/2024

[View](/en/documents/scientific-conclusion/oxbryta-h-c-psusa-00010983-202308-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Oxbryta : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/102184/2022

English (EN) (5.46 MB - PDF)

**First published:** 17/03/2022

[View](/en/documents/assessment-report/oxbryta-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Oxbryta

Adopted

Reference Number: EMA/CHMP/622322/2021

English (EN) (125.86 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-oxbryta_en.pdf)

#### News on Oxbryta

[EMA recommends suspension of sickle cell disease medicine Oxbryta](/en/news/ema-recommends-suspension-sickle-cell-disease-medicine-oxbryta) 26/09/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

[New treatment for sickle cell disease](/en/news/new-treatment-sickle-cell-disease) 17/12/2021

#### More information on Oxbryta

- [EU/3/16/1769 - orphan designation for treatment of sickle cell disease](/en/medicines/human/orphan-designations/eu-3-16-1769)
- [EMEA-002356-PIP02-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002356-pip02-20-m01)
- [Oxbryta - referral](/en/medicines/human/referrals/oxbryta)
- [Oxbryta - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/oxbryta)
- [An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)® (Voxelotor) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000170)
- [Effectiveness of voxelotor in individuals with sickle cell disease and a history of red blood cell transfusions: A non-interventional, retrospective cohort study using real-world data in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000225)
- [An observational, prospective study to assess the use, effectiveness, and safety of voxelotor in patients with sickle cell disease (SCD) in a real-life setting (VoxEval) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000186)
- [A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000334)

**This page was last updated on** 08/10/2024

## Share this page

[Back to top](#main-content)